With confidence dropping in doing business with China-affiliated life sciences companies due to the Biosecure Act, one of the companies explicitly named in the U.S. legislation is fighting back.
Korea Joongang Daily on MSN12h
Korean pharma seeks closer ties with Japan at Asia's largest biotech showKorean biopharmaceutical companies are exploring opportunities at Bio Japan 2024 amid U.S.-China tensions, with major firms ...
WuXi AppTec looks to unload its Philadelphia manufacturing sites and WuXi Biologics slows its rapid expansion in the U.S. as ...
The current status of the Biosecure Act is that it was passed ​ by the US House of Representatives on Sep 9, with a vote of ...
CHINA’S WuXi AppTec will raise US$500 million in a convertible bond sale, according to a regulatory filing on Tuesday (Oct 8) ...
WuXi AppTec Co. is raising $500 million through the sale of convertible bonds, becoming the latest Chinese company to turn to ...
China's WuXi AppTec , will raise $500 million in a convertible bond sale, according to a regulatory filing on Tuesday, a ...
On 9 September the US House of Representatives passed the draft of the Biosecure Act, which aims to prohibit US pharma ...
Samsung Biologics will participate in major conventions across Europe and Asia, aiming to secure new contracts from global ...
WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.
The gains were made on the back of a report that said the two firms plan to sell certain overseas operations amid heightened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback